6533b85dfe1ef96bd12bddd4

RESEARCH PRODUCT

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis

Angelo RavelliAngelo RavelliValeria GerloniAlessandro ConsolaroC MaggioAlberto MartiniAlberto MartiniDonato RiganteAdele CivinoBianca LattanziAntonella BuoncompagniGiulia BraccioliniMarco GattornoFranco GarofaloLoredana LeporeS DalpràStefania ViolaSergio DavìAntonella InsalacoLuciana BredaMaurizio GattinaraClara MalattiaClara MalattiaGiovanni FilocamoSilvia Magni-manzoniF De BenedettiN RupertoPaolo PiccoG PrestaAngela PistorioSara Verazza

subject

musculoskeletal diseasesPediatricsmedicine.medical_specialtyArthritislaw.inventionSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyRandomized controlled triallawInternal medicineSynovitismedicineImmunology and AllergyPediatrics Perinatology and Child Healthskin and connective tissue diseasesmethotrexate oligoarticular juvenile idiopathic arthritisOligoarthritisbusiness.industrymedicine.diseaseRheumatologyConcomitantPoster PresentationPediatrics Perinatology and Child HealthMethotrexateOligoarticular Juvenile Idiopathic Arthritisbusinessmedicine.drug

description

In contrast with the numerous controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular JIA. As a result, the management of children with this subtype, which is the most prevalent in Western countries, is largely empiric. Intra-articular corticosteroid (IAC) injection is the therapy of first choice for oligoarthritis in many pediatric rheumatology centers. However, although IAC injections are usually highly efficacious, relapses of synovitis are common and sometimes occur only a few months after the procedure. It is still unclear whether concomitant administration of methotrexate (MTX) may increase and prolong the effectiveness of IAC injections.

https://doi.org/10.1186/1546-0096-12-s1-p1